19Jul 2024
Molecular relapse after first-line intensive therapy in CBF or NPM1-mutated acute myeloid leukemia

Molecular relapse after first-line intensive therapy in CBF or NPM1-mutated acute myeloid leukemia

This retrospective study of 303 CBF and NPM1-mutated AML patients (aged 18-60) highlights the benefit of molecular monitoring and preemptive therapy over salvage therapy after morphologic relapse. Preemptive treatment significantly improved overall survival, suggesting its consideration in patient management.

  • #oncology

Like

Save

Share